AbbVie (NYSE: ABBV) Releases Phase 3 CLL14 Final Data at EHA 2026 Congress

AbbVie Inc. (NYSE: ABBV) presented final results from its Phase 3 CLL14 trial at the European Hematology Association 2026 Congress in Stockholm, Sweden on June 12, 2026, according to the company's announcement. The trial evaluated a fixed-duration venetoclax-based combination regimen in previously untreated chronic lymphocytic leukemia (CLL). Shares fell 0.56% on Wednesday, June 17, 2026, closing at $221.23.

CLL14 Trial Data: Key Details

• Trial design: Phase 3 CLL14 evaluated a fixed-duration venetoclax-based combination in patients with previously untreated CLL, according to AbbVie's announcement.
• Venue: Data were presented at the European Hematology Association 2026 Congress in Stockholm, Sweden.
• Announcement date: AbbVie disclosed the new data on June 12, 2026.
• Regimen structure: The trial assessed a fixed-duration approach, meaning patients receive treatment for a defined period rather than on a continuous basis.

Why It Matters

The CLL14 trial represents a clinically significant dataset for AbbVie's oncology franchise, as final Phase 3 results carry greater evidentiary weight than interim readouts and can inform label expansions, treatment guideline updates, and prescribing decisions. Fixed-duration regimens are a meaningful differentiator in CLL treatment, as they offer patients a defined treatment endpoint rather than indefinite therapy, which can affect tolerability and quality-of-life profiles.

Venetoclax, developed in partnership and marketed under the brand name Venclexta, anchors AbbVie's hematology pipeline. Presenting final data at a major international congress such as the EHA positions the clinical evidence for maximum visibility among the oncology community, potentially influencing adoption rates in the previously untreated CLL setting.

Wall Street View

Wall Street's consensus on AbbVie remains constructive. As of June 1, 2026, the analyst breakdown stood at 9 Strong Buy, 22 Buy, and 9 Hold ratings, with no Sell or Strong Sell calls recorded. The Hold count declined from 10 in the prior month's tally, reflecting a modest tightening of bullish conviction heading into the EHA data presentation.

Investor Takeaway

The release of final Phase 3 CLL14 data at EHA 2026 extends AbbVie's clinical evidence base for venetoclax in front-line CLL, a setting where treatment decisions are closely tied to long-term outcome data. With 31 of 40 tracked analysts carrying a Buy or Strong Buy rating as of June 1, 2026, the Street appears to view the hematology franchise as a credible contributor to AbbVie's broader portfolio alongside its immunology drugs.